Curcumin is an active component derived from Curcuma longa L. which is a traditional Chinese medicine that is widely used for treating metabolic diseases through regulating different molecular pathways. Here, in this study, we aimed to comprehensively investigate the effects of curcumin on glycolipid metabolism in vivo and in vitro and then determine the underlying mechanism. Male C57BL/6 J obese mice and 3T3-L1 adipocytes were used for in vivo and in vitro study, respectively. Our results demonstrated that treatment with curcumin for eight weeks decreased body weight, fat mass and serum lipid profiles. Meanwhile, it lowered fasting blood glucose and increased the insulin sensitivity in high-fat dietinduced obese mice. In addition, curcumin stimulated lipolysis and improved glycolipid metabolism through upregulating the expressions of adipose triglyceride lipase and hormonesensitive lipase, peroxisome proliferator activated receptor γ/α
Introduction
Obesity has become one of the most challenging health problems in the twenty-first century. The latest statistics showed that more than 1.0 billion adults worldwide were overweight; of these, over 400 million were obese [1] . It is usually accompanied with complex metabolic disorders, and significantly increases the risk of several common and serious diseases such as diabetes mellitus, hyperlipidaemia, hypertension, cardiovascular disease and non-alcoholic fatty liver disease [2] . Obesity is characterized by excessive accumulation of body fat (triglycerides (TGs)) in adipose tissue [3] . Interestingly, adipose tissue is not only an energy storage depot, but also a well-known endocrine organ secreting several cytokines and adipokines that are key determinants of whole-body energy homeostasis [4, 5] . Furthermore, dysfunction or excessive adipose storage of adipose tissue may lead to ectopic lipid accumulation and lipotoxicity in obese individuals and block insulin signalling transport [6, 7] .
Currently, various drugs have been approved by the US Food and Drug Administration to treat obesity in adults, but serious side effects of these drugs have limited their application [8, 9] . Fortunately, several commonly used medicinal plants and their bioactive compounds have been shown to prevent obesity and its related metabolic disorders in traditional Chinese medicine. Among them, curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, figure 1 ) is an active component derived from traditional herbal remedy and dietary spice turmeric (Curcuma longa L.), widely used in Ayurvedic and Chinese medicine for thousands of years [10, 11] . A large amount of experiments have demonstrated various biological activities of curcumin, including anti-inflammatory, anti-cancer and antioxidant [12, 13] . Curcumin protects rats from chronic inflammation observed in metabolic syndrome through inhibition of activation of NF-κB signalling [14, 15] . In addition, curcumin suppresses oxidation response of the pancreatic β cells by targeting PI3-k/Akt-mediated pathway and improves insulin-stimulated protein kinase B phosphorylation in the liver [16] . These reports indicated that curcumin exerted protective effects on metabolic diseases. Emerging evidence demonstrated that peroxisome proliferator activated receptor γ (PPARγ) is mainly involved in regulating lipid metabolism, insulin sensitivity and glucose homeostasis [17] . However, little is reported about the effects of curcumin on glycolipid metabolism through regulating PPARγ signalling both in vivo and in vitro.
Here, we investigated the effect of curcumin on glycolipid metabolism in high-fat diet (HFD)-induced obese mice and 3T3-L1 adipocytes and the potential mechanisms were also explored.
Material and methods

Chemicals
Curcumin was purchased from Sigma Chemical Co. (the purity was 99% tested by HPLC analysis). Blood glucose and TG kits were obtained from Beijing Leadman Biochemical Co. Ltd (Beijing, China). Assay kits for total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were obtained from Zhongsheng Beikong Biotechnology and Science Inc. (Beijing, China). Dulbecco's modified Eagle's medium (DMEM), penicillin-streptomycin (P/S), phosphate-buffered saline and trypsin-EDTA were purchased from Gibco (Grand Island, NA, USA). Insulin, dexamethasone (DEX), 3-isobutyl-1-methylxanthine (IBMX) and Oil Red O were purchased from Sigma (St Louis, MO, USA 
Experiment in mice
Mice were divided into two groups to receive different diets. Those in the control group were given AIN-96G diet with 5% corn oil (ND, n = 10), and the rest were fed with an MD12302 HFD containing 45% fat. The mice in the HFD group were confirmed as having obesity if their body weight was 20% greater than the mean of the control group. Then curcumin (HFD + Cur, n = 10) or saline (HFD, n = 10) were given by oral gavage for additional eight weeks. Body weight and fasting blood glucose (FBG) level were monitored weekly. The fat mass and oral glucose tolerance test (OGTT) were conducted at weeks 4 and 8. After eight-week treatment, mice were euthanatized with 1% sodium pentobarbital (0.4 ml/100 g) after fasting for 12 h. Subsequently, blood was collected from the abdominal aorta and centrifuged for 15 min at 3000 r.p.m. to obtain the serum. Epididymal white adipose tissue (WAT) was harvested from the mice. All samples for real-time polymerase chain reaction (RT-PCR) and western blotting analysis were stored at −80°C.
Oral glucose tolerance test
An OGTT was conducted at weeks 4 and 8. After fasting overnight, the oral glucose load was then administered at a dose of 2 g kg −1 body weight. Then, glucose contents were measured from the tail vein at 0, 30, 60 and 120 min after glucose administration. Area under the curve (AUC) was used to evaluate the glucose tolerance. Calculation formula was as follows: AUC (mmol h l −1 ) = 0.5 × (BG 0 min + BG 30 min)/2 + 0.5 × (BG 30 min + BG 60 min)/2 + 1 × (BG 60 min + BG 120 min)/2.
Serum biochemical analysis
Serum TG, TC, LDL-C and HDL-C were determined using commercial enzyme-linked immunosorbent assay kits in accordance with the manufacturer's protocols. Serum free fatty acid (FFA) level was measured using an enzymatic assay.
Cell culture and differentiation
The 3T3-L1 preadipocytes were cultured in DMEM supplemented with 10% fetal bovine serum and 1% P/S at 37°C, 5% CO 2 saturated humidity. The 3T3-L1 preadipocytes were grown to confluence in 24-well culture plates and differentiation was induced using a cocktail method. Briefly, cells were incubated in DMEM supplemented with MDI (0.5 mM IBMX, 1.0 µM DEX and 10 µg ml −1 insulin) for 2 days. Then the media were replaced with DMEM containing insulin (10 µg ml −1 ) for another 2 days. Thereafter, DMEM media were renewed every 2 days until cells reached the fully differentiated phenotype. 
RNA isolation and real-time polymerase chain reaction
Total RNA was isolated from the WAT and 3T3-L1 adipocytes using Trizol reagent according to the manufacturer's instructions. Then RT-PCR was performed according to the manufacturer's protocol (ABI 7500, Agilent, USA). The primers used in the experiments are shown in table 1. ARBP was employed as an endogenous control for normalization. RT-PCR data were analysed using the 2 − CT relative quantification method.
Western blotting analysis
WAT and 3T3-L1 adipocytes were lysed in RIPA buffer with protease inhibitor cocktail and quantified using the Micro BCA Protein Assay Kit. Forty micrograms of total protein per well were separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis. The protein was then transferred to PVDF membranes, and the membranes were then incubated overnight at 4°C with antibodies of adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), CCAAT/enhancer binding proteinα (C/EBPα), PPARγ and PPARα (1 : 1000 dilution). Secondary goat anti-rabbit immunoglobulin G antibody was incubated at a dilution of 1 : 2000. And in the end, blots were developed using ECL kit according to the manufacturer's protocol. For in vitro experiment, the membranes were then incubated with antibodies of C/EBPα, PPARγ (1 : 1000 dilution). Protein bands were visualized using IMAGEJ software. β-Actin (1 : 2000 dilution) was used as the internal control.
Statistical analysis
The results are presented as the mean ± standard error. One-way analysis of variance was used for multiple group comparisons, followed by Dunnett's test for comparison between two groups. The level of statistical significance was set at p < 0.05. 
Effects of curcumin on fasting blood glucose level and oral glucose tolerance test in high-fat diet-induced obese mice
The FBG levels of each group were measured weekly, as shown in figure 3a . Mice in the ND group maintained at normal FBG level, but the FBG level of the HFD group was significantly increased (p < 0.01). Compared with the HFD group, the FBG level began to decrease at the second week, and exhibited a maximum reduction at the fifth week in the HFD + Cur group (figure 3a; electronic supplementary material, data S3).
OGTT was conducted at weeks 4 and 8 (electronic supplementary material, data S4), and the results are shown in figure 3b-e . The AUC were higher in the HFD group than in the ND group. After fourand eight-week treatment with curcumin, the AUC in the HFD + Cur group were significantly reduced 33.6% and 35.5%, respectively, compared with the HFD group. In view of these results, curcumin could efficiently reduce FBG and improve obesity-induced OGTT and insulin sensitivity.
Effects of curcumin on serum lipid profile and free fatty acid levels in high-fat diet-induced obese mice
The serum TG, TC, LDL-C and FFA level in HFD mice were markedly increased by 6.4-, 1.5-, 4.0-and 1.9-fold, respectively, compared with the ND group. However, the HDL-C level was decreased by 21.2% in HFD mice. Treatment with curcumin significantly reduced TG, TC, LDL-C and FFA level by 16.1%, 17.1%, 22.6% and 15.4%, respectively, compared with the HFD group. But the HDL-C content was decreased by 60% compared with HFD mice ( figure 4 ; electronic supplementary material, data S5). These results demonstrated that curcumin markedly reduced the serum lipid levels and improved the disorders of lipid metabolism.
3.4. Effects of curcumin on mRNA and protein expression associated with peroxisome proliferator activated receptor γ signalling pathway in adipose tissue results indicated that curcumin stimulated lipolysis of adipose tissue through regulating the expression of ATGL and HSL. In addition, curcumin promoted glucose uptake and enhanced insulin sensitivity via upregulating the C/EBPα and PPARγ level.
Effect of curcumin on glycolipid metabolism in 3T3-L1 adipocytes
Curcumin increased basal glucose uptake of 3T3-L1 mature adipocytes by 1.2-, 1.6-and 1.0-fold in the presence of curcumin (10, 20 and 35 µM) compared with the control group (0 µM), and exhibited the maximum effect on glucose uptake at 20 µM (figure 6a). In addition, treatment with curcumin decreased the glycerol release by 74%, 69% and 64% compared with the control group (0 µM) (p < 0.01) (figure 6b). 
Discussion
In this present study, we investigated the effect of curcumin on anti-obesity and glycolipid metabolism and then explored the underlying mechanisms. Our major findings were that curcumin significantly reduced body weight, fat mass, blood serum lipid profiles and FBG level, and improved insulin resistance caused by obesity, indicating that curcumin acts on regulating glycolipid metabolism in HFD-induced obese C57BL/6 J mice. In differentiated 3T3-L1 adipocytes, curcumin increased glucose uptake and decreased glycerol release which coincided with the in vivo experiments. Curcumin is a hydrophobic polyphenol extracted from turmeric, which has been the subject of intensive researches due to its wide pharmacological activities [18] . A few clinical trials have shown the therapeutic effects of curcumin on metabolic syndrome [19, 20] . Moreover, Zhou et al. [21] showed that curcumin stimulates gene expression of PPARγ in activated hepatic stellate cells and interrupts PDGF and EGF signalling. In this study, we found that curcumin prevented body weight gain and reduced fat mass and exerted an anti-obesity effect in HFD-induced obese mice. In addition, insulin resistance is a widespread phenomenon in obesity and also a vital factor in the development of hypertension and hyperlipidaemia [22] . Moreover, in the few animal experiments that have been conducted, oral administration of curcumin significantly improved insulin resistance in STZ-induced diabetic rats and mice [23, 24] . This study demonstrated that curcumin not only exerted an anti-obesity effect but also reduced FBG level and improved insulin sensitivity in HFD-induced obese mice. Besides, curcumin markedly promoted glucose uptake in differentiated 3T3-L1 adipocytes, consistent with the in vivo experiments. The above results indicated curcumin has the ability to treat and prevent obesity and diabetes mellitus. Lipid metabolic disorders stimulate the excessive production of FFA in obese individuals, which subsequently decreases insulin-stimulated glucose uptake in the whole body [25, 26] . Asai et al. [27] reported that curcumin lowered the level of FFA through stimulating the expression of ACO, and further improved lipid metabolism. In our study, we found curcumin markedly reduced the FFA level after curcumin administration in the HFD + Cur group. And in the in vitro experiment, curcumin decreased glycerol release in differentiated 3T3-L1 adipocytes. These results suggested that curcumin has a certain effect on regulating lipid metabolism dysfunction.
Adipose tissue functions as an endocrine organ secreting several cytokines and adipokines that are key determinants of whole-body energy homeostasis [6] . It is well known that PPARγ and C/EBPα mutually induce adipocyte differentiation and function [28] . Recently, genome-wide profiling revealed PPARγ and C/EBPα to have a high overlap in adipocytes, suggesting that cooperativeness could be mediated through common binding sites. Moreover, PPARγ and C/EBPα play an important role in driving insulin-stimulated glucose uptake [29] . In this study, curcumin increased the mRNA and protein expression of PPARγ and C/EBPα in mice and in differentiated 3T3-L1 cells. These results indicated that curcumin promoted glucose uptake and improved insulin resistance through upregulating the expression of PPARγ and C/EBPα. But high dose (35 µM) of curcumin did not significantly upregulate the protein expression of PPARγ and C/EBPα in 3T3-L1 cells. We hypothesize that 35 µM curcumin may have an effect on the activity of some enzymes in the process of translating into proteins, so further study and discussions deserve to be explored in the future.
In addition, we found that curcumin administration led to the activation of lipolysis in WAT. WAT is a metabolic flexible tissue, which is important for energy storage or energy source release in the form of adipogenesis and lipolysis of TGs [5] . As reported, activation of PPARγ enhanced lipolysis of circulating TGs and their storage in adipose tissue [30, 31] . A study reported that PPARγ signalling regulated the lipolytic response through its modulatory effect on adipose tissue lipases including ATGL and HSL that hydrolysed intracellular triacylglycerol and diacylglycerol to release FFA and glycerol [32] . In this study, we found that curcumin significantly increased the mRNA and protein expression of ATGL and HSL in HFD-induced obese mice. All above results indicate that curcumin improved glycolipid metabolism and enhanced insulin sensitivity through regulating PPARγ signalling pathway in vivo and in vitro. 
Conclusion
Curcumin administration reduced body weight, lowered the blood glucose level and serum lipid profiles and improved insulin sensitivity in obese mice through regulating the PPARγ signalling in adipose tissue. The results suggest that curcumin seems to offer potency as a traditional plant extract that is useful to prevent and treat obesity and diabetes. 
